Tuesday 31 January

Strategies for the UPC: from tech start-up to big pharma

When and where

Date and time

Start: Tuesday 31 January 2023, 12:30 PM

End: Tuesday 31 January 2023, 01:30 PM

Event Overview

This long-awaited panel session brings together representatives from across industry to give their views on the unitary patent and the UPC. Originally scheduled as part of (the unfortunately cancelled) CIPA Congress 2022, CIPA are pleased to be able to bring this session to their members in webinar form. In-house attorneys from BAE, IBM and MSD are joined by private practice attorneys to discuss strategy options for the new system in their respective technology fields, and to comment on how these strategies might vary for different types of clients, from start-ups and SMEs through to multinationals.

***Please note the bookings for this webinar have closed, to book for this webinar please get in touch with [email protected]***


Members, Non Members, All


Belinda Gascoyne, IBM EMEA & AP

Belinda Gascoyne, IBM EMEA & AP

Belinda is Senior IP Law Counsel at IBM where she heads up the IP Law teams in Europe, Middle East and Africa (EMEA) and Asia-Pacific (AP), which together provide all aspects of IP Law support for IBM in all geographies outside the Americas. Belinda is a Chartered and European Patent Attorney with a background in Physics and has wide practical experience in drafting, filing and prosecuting patent applications as well as in IP strategy, patent management and copyright issues. Before joining IBM in 2004, Belinda worked in private practice in London.

Belinda is also actively involved in UK and European IP policy matters and is a former President, and a Council member of, the IP Federation, and has been named for several years running by Managing IP as one of its “Corporate IP Stars”.

James Horgan, Merck Sharp & Dohme LLC

James Horgan, Merck Sharp & Dohme LLC

James Horgan is Assistant Managing Counsel at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. He heads the European Patent Department based in London. He has a degree in chemistry and has practiced extensively in the pharmaceutical, vaccine and biotechnological fields for 25 years supporting research sites in England and Italy. He has wide experience of prosecuting applications before the EPO where he appears in ex parte and inter partes Oral Proceedings. He has filed and prosecuted a large number of SPCs. He has been involved in major multi-jurisdictional litigation in cases relating to Vioxx, Fosamax, Cosopt, Propecia, Rebetol, Isentress, Inegy and Janumet with major successes before the Dutch, Irish and Malaysian Supreme Courts in cases relating to second medical use claims, the standards for preliminary injunctions and the judicial assessment of subclaims, as well as before the CJEU and EFTA courts in cases relating to parallel imports and negative term SPCs. He has two ongoing CJEU cases which relate to the interplay of Artr 3(a) and (c) of the SPC Regulation.

He is involved in IP policy issues via the IP Federation, where he was President in 2017-18, EFPIA, IFPMA and Business Europe. He has been included in the IAM list of the World’s 300 Leading IP Strategists employed in industry since its inception in 2015, and is also one of Managing Intellectual Property’s Corporate IP Stars.

Rachel Bateman, D Young & Co

Rachel Bateman, D Young & Co

Rachel joined D Young & Co in 2012 with a general chemical background from a first class Chemistry degree at the University of Oxford. Her portfolio covers a wide range of chemical subject-matter including fuel additives, petroleum and natural gas exploration, antibiotics, pharmaceuticals, polymers, pigments, dyes, food technology, semiconductors, medical devices and nanotechnology. Rachel’s day-to-day work includes drafting patent applications, coordinating multi-territory prosecution, handling EPO opposition and appeal cases, as well as preparing freedom-to-operate opinions for pharma generics or innovators. She has experience arguing before the EPO Opposition Divisions and Appeal Boards and has been involved in several important cases in the areas of fuel additives, food technology and pharmaceuticals.

Rachel has received numerous accolades throughout her career, including the Gibbs prize for final exam results from the University of Oxford, the GlaxoSmithKline prize for patents from Queen Mary University of London and CIPA’s Ballantyne prize for top marks in UK finals. Rachel is a key member of D Young & Co’s Unitary Patent and Unified Patent Court team and has a keen interest in the developments of this new system. Rachel has been recommended for her services by Legal 500 and ranked as a “notable practitioner” by IPSTARS (Managing IP).

The event has been added to your basket:

Strategies for the UPC: from tech start-up to big pharma

Proceed to basket

Shopping Basket

No products in the cart.

Are you a CIPA member?

Sign in to your account to register for the event

Forgotten password?

If you are not yet registered or a member of CIPA, please register here

Skip to content